nal carotid artery systems. The preoperative diagnosis was convexity meningioma in the right frontal area.
Operation. A frontotemporal craniotomy was performed and the mass was found to be attached to the convexity dura mater with no invasion of the adjacent brain tissues. Total removal of the mass was performed without difficulty, and the immediate postoperative clinical course was uneventful.
Histopathological Findings. The resected tumor measured 6.5 ϫ 6.5 ϫ 4.5 cm, and the cut surfaces were pinkish gray and somewhat myxoid. Histologically, the tumor was characterized by an abundant myxoid matrix. Although some areas were solid enough to suggest a meningothelial pattern of meningioma, the larger portions of the tumor tissue consisted of looser zones with myxoid matrix and clusters of cells that had small or large intracellular vacuoles (Fig. 2) . The cells appeared spindly or multipolar and formed clusters and rows in patterns that resembled chordomas. Unlike the chordoid meningiomas hitherto described, dense infiltrations of lymphocytes and plasma cells were absent. Marked nuclear pleomorphism was noted focally. Mitoses were noted at up to two per 10 highpower fields in the most active areas. Intravascular tumor emboli were also present in the dura. However, brain parenchymal invasion was absent (Fig. 3) . Immunohistochemical studies revealed that the tumor cells expressed EMA diffusely and cytokeratin focally, but not S-100 protein. The cytokeratin-positive cells possessed abundant cytoplasm compared with cytokeratin-negative tumor cells. Squamoid cells with abundant thick cytoplasm were scattered in the tumor, and these cells were suspected of expressing cytokeratin (Fig. 4) . Immunohistochemical studies also revealed that the Ki-67 proliferative index of the tumor was 10%. Immunoexpression of p53 protein was occasionally noted in fewer than 1% of tumor cells. On the basis of these findings, a histological diagnosis of chordoid meningioma was made.
Postoperative Course. Complete resolution of neurological symptoms was found at the 1-month follow-up review and the patient's gammaglobulin level had normalized at the 6-month follow up. Serum protein electrophoresis follow-up data in this patient is summarized in Fig. 5 .
Discussion

Literature Review
Meningioma is a common intracranial tumor that occurs usually in the fifth and sixth decades of life and accounts for approximately 15% of primary central nervous system tumors. The first histological classification of meningioma was made in 1938 by Cushing and Eisenhardt, 6 and thereafter, many revisions of the classification system have been made by different authors. In the WHO classification of brain tumors 12 published in 1993, which is the most recent and accepted worldwide, several new variants such as microcystic, secretory, clear-cell, lymphoplasmacyte-rich, metaplastic, and chordoid subtypes were included in the classification of meningioma. Chordoid meningioma is a rare variant of the tumor that occurs in adolescence and shows systemic symptoms of Castleman syndrome. Thirteen cases of chordoid meningioma have been reported, and these cases are summarized in Table   1 . 4, 5, 7, 8, 11, 13, 14, 20 All reported cases of chordoid meningioma, except one, have occurred in the first three decades of life. Locations of tumors were not exceptional compared with the usual type of meningioma. Anemia was present in all eight cases in which appropriate clinical information was reported. Full-blown Castleman syndrome, including polyclonal gammopathy, was present in one case. The evolution of Castleman syndrome after surgical removal of the tumor was described in eight cases. Chordoid meningioma with polyclonal gammopathy as the only sign of Castleman syndrome has not been reported yet, and occurrence of such tumors in the sixth decade of life is unusual.
Histological Findings
The histological appearance of chordoid meningioma is characterized by its resemblance to chordoma on light microscopy studies. 10 Compared with the chordoid meningioma hitherto described, the histopathological characteristics of this case were as follows: first, a meningothelial pattern was noted focally; second, cytokeratin-positive squamoid cells were present; and third, the tumor lacked dense infiltration of lymphocytes and plasma cells.
Differentiation from chordoma can be established from the location of the tumor and the immunohistopathological findings. Chordoma is usually located in midline structures such as the clivus or sellar area, but chordoid meningioma is not closely associated with the midline. Immunohistochemical staining for EMA, vimentin, and cytokeratin is strongly positive and that for S-100 protein is partially positive in chordoma. 1, 18 In chordoid meningioma, immunohistochemical staining for EMA and vimentin is positive and that for cytokeratin and S-100 protein is negative. 13, 21 In our case, the tumor cells expressed EMA diffusely and cytokeratin focally. Squamoid cells with abundant thick cytoplasm expressed cytokeratin; however, most tumor cells were negative for cytokeratin. In addition, the focal presence of a meningothelial meningiomatous pattern indicates that chordoid meningiomas originate from meningothelial cells. Another differential diagnosis that can be established using histopathological studies is extraneural chordoid sarcoma (extraskeletal myxoid chondrosarcoma). 17 Generally, chordoid meningioma is distinguished from extraneural chordoid sarcoma by the patient's age at occurrence, which is much older. The histopathological pattern of extraneural chordoid sarcoma features more anaplasia and more marked lymphoplasmacellular infiltrations than that of chordoid meningioma. 11 In this case, differentiation from extraneural chordoid sarcoma was made on the basis of the pathological findings that some areas of the tumor were solid enough to establish a meningothelial pattern of meningioma and also that the tumor cells expressed EMA and cytokeratin but not S-100 protein.
Castleman Syndrome
In 1954 and 1956 Castleman and colleagues 2,3 reported cases of mediastinal lymphoid masses resembling thymic tissue, which contained bodies reminiscent of Hassall's corpuscles that represented vascular structures involving lymph follicles. Castleman named this lesion an "angiofollicular hyperplasia" of the lymph node (Castleman disease). Keller, et al., 9 reported that localized Castleman disease had a benign clinical course and subdivided it into hyaline-vascular and plasma cell types. Thereafter, extrathoracic angiofollicular hyperplasia of lymph nodes began to be reported. In 1965, Lee, et al., 15 reported cases of plasmacellular types of Castleman disease accompanied by iron-refractory hypochromic anemia. In 1968, Luthi, et al., 16 and the next year Neerhout, et al., 19 reported subsequent cases with other systemic manifestations like growth failure and hyperglobulinemia. In 1980, Connors 5 reported a case of brain tumor in a 15.5-year-old boy with retarded somatic and sexual development, hepatosplenomegaly, iron-refractory hypochromic microcytic anemia, and bone marrow plasmacytosis with dysgammaglobulinemia (Castleman syndrome). The patient underwent subtotal removal of the lesion and postoperative radiotherapy, and Castleman syndrome then disappeared. However, the histological diagnosis of the brain tumor was not made at that time. In 1988, Kepes, et al., 11 presented six additional cases with histological and clinical features similar to those in the case reported by Connors, and they named these tumors chordoid meningiomas. These lesion were characterized by occurrence in adolescence, a chordomalike histological appearance with lymphoplasmacellular infiltrations, and an association with Castleman syndrome. Chordoid meningioma was included as a new category in the recent WHO classification of brain tumors 12 as a subtype of meningioma. Thirteen cases of chordoid meningioma have been reported to date, and these cases showed similar clinical features. Among the signs of Castleman syndrome, hypochromic microcytic anemia was found in all the reported cases of this disorder; however, our patient did not have anemia. The cause of Castleman syndrome in chordoid meningiomas is still unknown; however, immunological host reactions to the tumor were suggested by Kepes, et port occurred in the sixth decade of the patient's life, and of the documented signs of Castleman syndrome, she exhibited only polyclonal gammopathy, which is considered a kind of response to immune stimulation. We believe that in this patient her relatively old age might have caused the different host reaction. In discussing the immune response in relation to the patient's age, Kepes, et al., 11 stated that older individuals seem to be less susceptible to systemic effects of Castleman syndrome than younger ones.
Conclusions
Chordoid meningioma must be included in the preoperative differential diagnosis of brain tumor featuring only polyclonal gammopathy, even in an older patient, although the incidence of chordoid meningioma is quite low in this age group. The clinical outcome is favorable, and systemic manifestations also resolve after removal of the mass.
